%0 Journal Article
%T Dual
%A Aijing Sun
%A Fang Liu
%A Feng Tao
%A Guangen Xu
%A Jieqing Lv
%A Minfeng Ye
%A Wei Wang
%A Xue Wu
%A Yang W. Shao
%A Yichuan Liu
%A Yuanming Jing
%A Zengxin Lu
%J Journal of International Medical Research
%@ 1473-2300
%D 2019
%R 10.1177/0300060519847796
%X Gallbladder carcinoma (GBC) is a rare and highly aggressive tumor. Early diagnosis is challenging, which results in a poor prognosis using systemic therapy. Recent studies have identified a subset of GBC patients with HER2 gene (ERBB2) amplification that could benefit from HER2-targeted therapy. Here, we report one patient with recurrent metachronous GBC with metastasis, who received the combination of trastuzumab and lapatinib. This approach achieved a partial response for both the brain and the lung metastases. This study demonstrated that HER2 inhibition is a promising therapeutic strategy for GBC with HER2 amplification and, combined with lapatinib, it can effectively target brain metastasis
%K Gallbladder carcinoma
%K HER2 amplification
%K dual-targeted therapy
%K trastuzumab
%K lapatinib
%K tumor
%U https://journals.sagepub.com/doi/full/10.1177/0300060519847796